Tralokinumab
Interleukin-13 Antagonist — DERMATOLOGICALS
Also known as: adbry, adtralza, CAT-354
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tralokinumab is a drug in the Interleukin-13 Antagonist class catalogued in DrugCentral. It was first approved by the EMA in 2021. Its mechanism of action is classified as Interleukin-13 Antagonists. DrugCentral lists 1 molecular target, including IL13. Recorded indications include Moderate to severe atopic dermatitis.
- Drug class: Interleukin-13 Antagonist.
- Mechanism of action: Interleukin-13 Antagonists.
- Molecular targets: IL13 (1 listed in DrugCentral).
- Indications: Moderate to severe atopic dermatitis.
- ATC code: D11AH07 (Agents for dermatitis, excluding corticosteroids).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Moderate to severe atopic dermatitis
Mechanism & targets
| Mechanism of action (MoA) | Interleukin-13 Antagonists |
|---|---|
| Established pharmacologic class | Interleukin-13 Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Interleukin-13 | IL13 | other | Kd 10.22 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-12-23 | PMDA | — | Leo Pharma K.K. | |
| 2021-12-27 | FDA | — | LEO PHARMA AS | |
| 2021-07-16 | EMA | — | LEO PHARMA A/S |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D11AH07 | DERMATOLOGICALS › OTHER DERMATOLOGICAL PREPARATIONS › OTHER DERMATOLOGICAL PREPARATIONS › Agents for dermatitis, excluding corticosteroids |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Pruritus | 653.5 |
| Drug ineffective | 438.0 |
| Eczema | 405.8 |
| Dry skin | 399.4 |
| Dermatitis atopic | 373.4 |
| Conjunctivitis | 296.1 |
| Injection site pain | 280.9 |
| Rash | 277.3 |
| Eye pruritus | 275.9 |
| Ocular hyperaemia | 264.7 |
| Skin exfoliation | 231.0 |
| Injection site pruritus | 227.6 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1044515-88-9 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tralokinumab used for?
DrugCentral lists the following indications for Tralokinumab: Moderate to severe atopic dermatitis.
How does Tralokinumab work?
Tralokinumab is classified as Interleukin-13 Antagonists; its molecular targets in DrugCentral include IL13.
When was Tralokinumab first approved?
Tralokinumab was first approved by the EMA in 2021.
What drug class does Tralokinumab belong to?
Tralokinumab is in the Interleukin-13 Antagonist class.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5479 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1743081 — compound record and bioactivity
- DrugBank DB12169 — drug record
- FDA UNII GK1LYB375A — substance identity
- DailyMed: FDA labels for Tralokinumab — current prescribing information (label search)
- UniProt P35225 (IL13) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.